By: IPP Bureau
Last updated : June 23, 2026 1:28 pm
As per the company’s Restated H1 2025 Financials, its continuing business delivered CORE EBITDA of CHF 922 million, representing a margin of 30.4%
Ahead of the release of its Half-Year 2026 results on July 22, Lonza has published restated financial information for the first half of 2025 to reflect the classification of its Capsules & Health Ingredients (CHI) business as discontinued operations.
The restatement follows Lonza's strategic decision to divest the CHI business, first announced in December 2024. The company subsequently entered into a definitive agreement on March 6, 2026, to sell the business to Lone Star Funds, with the transaction expected to close during the third quarter of 2026.
Under the revised reporting structure, Lonza's continuing operations generated sales of CHF 3.03 billion during the six months ended June 30, 2025, compared with CHF 3.58 billion for the group as originally reported.
The discontinued CHI business contributed CHF 542 million in sales during the period.
Continuing operations reported earnings before interest and taxes (EBIT) of CHF 573 million, representing an EBIT margin of 18.9%, while the CHI business contributed CHF 44 million in EBIT with a margin of 8.1%.
EBITDA from continuing operations stood at CHF 877 million, corresponding to an EBITDA margin of 28.9%. Including the discontinued operations, group EBITDA was CHF 1.01 billion. The CHI business accounted for CHF 129 million of EBITDA during the period.
Profit from continuing operations reached CHF 396 million, while the discontinued CHI business contributed CHF 30 million, resulting in total profit for the period of CHF 426 million. Basic earnings per share (EPS) from continuing operations were CHF 5.68, compared with reported group EPS of CHF 6.08.
On a CORE basis, Lonza's continuing business delivered CORE EBITDA of CHF 922 million, representing a margin of 30.4%. The CHI business contributed CHF 137 million of CORE EBITDA, bringing total group CORE EBITDA to CHF 1.06 billion. Return on Invested Capital (ROIC) for the continuing business improved to 10.5%.
Operational free cash flow before acquisitions and divestitures amounted to CHF 116 million for continuing operations, while total operational free cash flow stood at CHF 68 million.
Capital expenditures for continuing operations reached CHF 642 million during the reporting period, reflecting Lonza's continued investments in manufacturing capacity and growth projects.